Robert Maronpot

/Robert Maronpot

About Robert Maronpot

Dr. Maronpot received his doctorate of veterinary medicine in 1965 from Michigan State University, an MS in nutritional pathology from Michigan State University in 1966, and an MPH from Harvard University in 1972. He is a diplomate of the American College of Veterinary Pathologists as well as the American Board of Toxicology and has worked more than forty years in experimental pathology, with an emphasis on animal models of carcinogenesis.

Recommendations from the INHAND Apoptosis/Necrosis Working Group

2017-01-11T22:13:22+00:00

Historically, there has been confusion relating to the diagnostic nomenclature for individual cell death. Toxicologic pathologists have generally used the terms ‘‘single cell necrosis’’ and ‘‘apoptosis’’ interchangeably. Increased research on the mechanisms of cell death in recent years has led to the understanding that apoptosis and necrosis involve different cellular pathways and that [...]

Recommendations from the INHAND Apoptosis/Necrosis Working Group 2017-01-11T22:13:22+00:00

Safety Assessment and Single-dose Toxicokinetics of the Flavouring Agent Myricitrin in Sprague–Dawley Rats

2017-01-11T22:13:22+00:00

Myricitrin, a flavonol rhamnoside of myricetin extracted from the Chinese bayberry (Myrica rubra Siebold) plant, has been used in Japan since 1992 as a flavour modifier in snack foods, dairy products, and beverages. It is affirmed as generally recognised as safe (GRAS) by the US Flavour and Extract Manufacturer Association (FEMA) and is [...]

Safety Assessment and Single-dose Toxicokinetics of the Flavouring Agent Myricitrin in Sprague–Dawley Rats 2017-01-11T22:13:22+00:00

Genotoxicity Evaluation of the Flavonoid, Myricitrin, and its Aglycone, Myricetin

2017-01-11T22:13:22+00:00

Myricitrin, a flavonoid extracted from the fruit, leaves, and bark of Chinese bayberry (Myrica rubra SIEBOLD), is currently used as a flavor modifier in snack foods, dairy products, and beverages in Japan. Myricitrin is converted to myricetin by intestinal microflora; myricetin also occurs ubiquitously in plants and is consumed in fruits, vegetables, and beverages. [...]

Genotoxicity Evaluation of the Flavonoid, Myricitrin, and its Aglycone, Myricetin 2017-01-11T22:13:22+00:00

Toxicological Assessment of Ashitaba Chalcone

2017-01-11T22:13:22+00:00

The plant Angelica keiskei contains two main physiologically active flavonoid chalcones, 4-hydroxyderricin and xanthoangelol. Known as ashitaba in Japan, powder from the sap is widely consumed for its medicinal properties in Asia as a dietary supplement. Limited previously reported mammalian studies were without evidence of toxicity. GLP studies reported here, including a bacterial [...]

Toxicological Assessment of Ashitaba Chalcone 2017-01-11T22:13:22+00:00

Human Relevance Of Rodent Leydig Cell Tumors

2017-01-11T22:13:22+00:00

Rodents have been used extensively in virtually all fields of biomedical research and have been the primary species used in toxicologic and carcinogenic research. Over many years it has become obvious that some conditions and in particular some tumors in rodents have questionable relevance in humans. Some of these include peroxisome proliferatoractivator receptor-α [...]

Human Relevance Of Rodent Leydig Cell Tumors 2017-01-11T22:13:22+00:00

Two-year Carcinogenicity Study of Acrylamide in Wistar Han Rats with In Utero Exposure

2017-01-11T22:13:22+00:00

Acrylamide is an important chemical with widespread industrial and other uses in addition to generalized population exposure from certain cooked foods. Previous rat studies to assess the carcinogenic potential of acrylamide have been carried out exclusively in the Fischer 344 rat with identification of a number of tumors amongst which mesotheliomas of the [...]

Two-year Carcinogenicity Study of Acrylamide in Wistar Han Rats with In Utero Exposure 2017-01-11T22:13:22+00:00

Practical Applications of in Vivo and ex Vivo MRI in Toxicologic Pathology Using a Novel High-performance Compact MRI System

2017-01-11T22:13:22+00:00

Catherine Tempel-Brami, Yael S. Schiffenbauer, Abraham Nyska, Nati Ezov, Itai Spector, Rinat abramovitch, and Robert R. Maronpot Magnetic resonance imaging (MRI) is widely used in preclinical research and drug development and is a powerful noninvasive method for assessment of phenotypes and therapeutic efficacy in murine models of disease. In vivo MRI provides an [...]

Practical Applications of in Vivo and ex Vivo MRI in Toxicologic Pathology Using a Novel High-performance Compact MRI System 2017-01-11T22:13:22+00:00

Long-term Local and Systemic Safety of Poly(L-lactide-co-epsilon-caprolactone) after Subcutaneous and Intra-articular Implantation in Rats

2017-01-11T22:13:22+00:00

Abstract The use of biodegradable materials is gaining popularity in medicine, especially in orthopedic applications. However, preclinical evaluation of biodegradable materials can be challenging, since they are located in close contact with host tissues and might be implanted for a long period of time. Evaluation of these compounds requires biodegradability and biocompatibility studies [...]

Long-term Local and Systemic Safety of Poly(L-lactide-co-epsilon-caprolactone) after Subcutaneous and Intra-articular Implantation in Rats 2017-01-11T22:13:22+00:00

Histopathology of biodegradable polymers: challenges in interpretation and the use of a novel compact MRI for biocompatibility evaluation

2017-01-11T22:13:22+00:00

Toxicologic pathology is the art of assessment of potential adverse effects at the tissue level in pre-clinical studies. In the case of biomaterials and medical devices, the toxicologic pathologists assess the safety (biocompatibility) and efficacy (conditions of the use) of the implantable materials. Proper assessment of biocompatibility of biomaterials is of utmost importance, [...]

Histopathology of biodegradable polymers: challenges in interpretation and the use of a novel compact MRI for biocompatibility evaluation 2017-01-11T22:13:22+00:00

The Role of the Toxicologic Pathologist in the Post-Genomic Era

2017-01-11T22:13:22+00:00

An era can be defined as a period in time identified by distinctive character, events, or practices. We are now in the genomic era. The pre-genomic era: There was a pre-genomic era. It started many years ago with novel and seminal animal experiments, primarily directed at studying cancer. It is marked by the [...]

The Role of the Toxicologic Pathologist in the Post-Genomic Era 2017-01-11T22:13:22+00:00